Digestive Center, E-DA Hospital, Taipei, Taiwan.
J Gastroenterol Hepatol. 2009 Jun;24(6):982-7. doi: 10.1111/j.1440-1746.2009.05792.x.
BACKGROUND & AIMS: Both medications with beta-blockers and isosorbide-5-mononitrate and endoscopic variceal ligation have been proven plausible in the prevention of variceal rebleeding. However, the relative efficacy and safety of the combined treatment for preventing rebleeding remains unresolved.
Patients with history of esophageal variceal bleeding were enrolled. Emergency ligation was performed in patients with acute variceal bleeding. After hemodynamic stability, eligible patients were randomized to either the Medication group, using nadolol plus isorsorbide-5-mononitrate, or the Combined group, receiving banding ligation in addition to medications. Patients in the two groups with rebleeding from esophageal varices were treated with band ligation. The end points were rebleeding from varices or death.
After a median follow up of 23 months, recurrent upper gastrointestinal bleeding developed in 51% in the Medication group and 38% in the Combined group (P = 0.21). Recurrent bleeding from esophageal varices occurred in 26 patients (43%) in the Medication group and in 16 patients (26%) in the Combined group (P = 0.07). Recurrent bleeding from gastroesophageal varices occurred in 48% of Medication group and 28% of Combined group (P = 0.05). The frequency of adverse effects and mortality rates were similar between both groups (P = 0.28).
Combined ligation with medications was marginally more effective than medication alone in the prevention of gastroesophageal variceal rebleeding with similar adverse effects and mortality.
β受体阻滞剂和单硝酸异山梨酯与内镜下食管静脉曲张套扎术均已被证明可合理预防静脉曲张再出血。然而,联合治疗预防再出血的相对疗效和安全性仍未解决。
入组有食管静脉曲张出血史的患者。急性静脉曲张出血的患者行紧急套扎。血流动力学稳定后,合格的患者随机分为药物组,使用纳多洛尔加单硝酸异山梨酯;或联合组,除了药物治疗外还接受套扎治疗。两组中因食管静脉曲张再出血的患者均接受套扎治疗。终点为静脉曲张再出血或死亡。
中位随访 23 个月后,药物组有 51%的患者出现再发性上消化道出血,联合组有 38%的患者出现再发性上消化道出血(P = 0.21)。药物组有 26 例(43%)患者出现食管静脉曲张再出血,联合组有 16 例(26%)患者出现食管静脉曲张再出血(P = 0.07)。药物组再出血的发生率为 48%,联合组为 28%(P = 0.05)。两组的不良反应发生率和死亡率相似(P = 0.28)。
与单独药物治疗相比,联合套扎加药物治疗在预防胃食管静脉曲张再出血方面略有优势,且不良反应和死亡率相似。